67 completed, 26 terminated, 16 recruiting, 12 active not recruiting. 79 Phase 2, 51 Phase 1, 13 Phase 3, 4 Phase 4, 3 Early Phase 1.
Follow Vemurafenib: new trials by email Literature Review of Vemurafenib trials Research Report on Vemurafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) Vemurafenib, Obinutuzumab, Cladribine - Hairy Cell Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 86 | 2024-09-09 | 2026-09-09 |
| Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer FOLFIRI + Vemurafenib + Cetuximab, FOLFIRI ± Bevacizumab - Colorectal Carcinoma | Phase 2 | Recruiting | Shanghai Changzheng Hospital | 75 | 2024-09-01 | 2024-09-19 |
| Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation Biospecimen Collection, Cobimetinib, Computed Tomography - Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 21 | 2024-07-15 | 2026-02-02 |
| Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab - Colorectal Cancer Metastatic | Phase 3 | Recruiting | Shanghai Kechow Pharma, Inc. | 165 | 2023-10-25 | 2026-09-09 |
| DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 825 | 2023-03-01 | 2026-07-01 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II Alectinib, Atezolizumab, Erlotinib - Solid Tumor, Advanced Solid Tumor | Active not recruiting | Seoul National University Bundang Hospital | 1000 | 2022-09-28 | 2026-09-30 | |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Low dose vemurafenib plus rituximab - Hairy Cell Leukemia | Phase 2 | Completed | Scripps Health | 15 | 2022-03-02 | 2026-04-24 |
| Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC) HL-085, Vemurafenib - CRC | Phase 2 | Unknown | Shanghai Kechow Pharma, Inc. | 186 | 2022-02-24 | 2023-05-31 |
| Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US Encorafenib, Binimetinib, Vemurafenib - Melanoma | Completed | Pfizer | 716 | 2022-01-17 | 2025-03-06 | |
| a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors Targeted therapy - Feasibility, Effectiveness | Unknown | The University of Hong Kong-Shenzhen Hospital | 120 | 2021-12-30 | 2022-01-04 | |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2024-07-15 |
| Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer Vemurafenib, Sorafenib - Pancreas Cancer | Phase 2 | Completed | HonorHealth Research Institute | 10 | 2021-10-28 | 2026-03-30 |
| CRAFT: The NCT-PMO-1602 Phase II Trial Vemurafenib, Cobimetinib, Atezolizumab - Metastatic or Locally Advanced Malignancies | Phase 2 | Completed | German Cancer Research Center | 72 | 2021-10-13 | 2025-01-08 |
| Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study Trametinib, Cobimetinib, Binimetinib - Cancer | Not applicable | Terminated | Peter MacCallum Cancer Centre, Australia | 3 | 2021-09-23 | 2023-05-10 |
| HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation HL-085, Vemurafenib - Melanoma | Phase 2 | Unknown | Shanghai Kechow Pharma, Inc. | 104 | 2021-09-06 | 2023-05-31 |
| Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer Vemurafenib Oral Tablet [Zelboraf], Cetuximab Injection [Erbitux], Camrelizumab - BRAF V600E-mutated /MSS Metastatic Colorectal Cancer, Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody | Phase 1 | Unknown | West China Hospital | 12 | 2021-08-15 | 2022-05-19 |
Showing 20 of 144. Sign in to see all of them.
Melanoma (71) · Neoplasms (28) · Neoplasm Metastasis (15) · Colorectal Neoplasms (9) · Multiple Myeloma (6) · Carcinoma, Non-Small-Cell Lung (5) · Lymphoma, Non-Hodgkin (5) · Skin Neoplasms (5) · Thyroid Neoplasms (5) · Hematologic Neoplasms (4) · Histiocytosis, Langerhans-Cell (4) · Leukemia, Hairy Cell (4) · Thyroid Cancer, Papillary (4) · Breast Neoplasms (3) · Glioma (3)
Hoffmann-La Roche (30) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (7) · Genentech, Inc. (5) · National Cancer Institute (NCI) (4) · Shanghai Kechow Pharma, Inc. (4) · Fondazione Melanoma Onlus (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Pfizer (3) · Bristol-Myers Squibb (2) · Cancer Research UK (2) · Massachusetts General Hospital (2) · OHSU Knight Cancer Institute (2) · Oslo University Hospital (2) · Shanghai Changzheng Hospital (2)
United States (86) · Germany (25) · France (22) · Italy (22) · Australia (20) · Netherlands (20) · Spain (20) · United Kingdom (19) · Canada (17) · Israel (16) · Russia (15) · South Korea (15) · Brazil (14) · China (13) · Poland (13)
Hongqi Tian, Ph.D (3) · Jae Park, MD (2) · Matthew Krebs, Dr (2) · Michael B Atkins, MD (2) · Mohammed Milhem, MD (2) · Ravi Amaravadi, MD (2) · Zeynep Eroglu, M.D. (2) · Adil Daud, MD (1) · AeRang Kim (1) · Alan L Ho, MD, PhD (1) · Alan L. Ho, MD, PhD (1) · Alan Saven, MD (1)
PMID 32746839, PMID 22256804, PMID 23457002, PMID 24577748, PMID 24983357, PMID 36648215, PMID 36653848, PMID 20818844, PMID 20921468, PMID 21639808, PMID 22356324, PMID 22397650, PMID 22431777, PMID 22651703, PMID 22966018, PMID 23415641, PMID 24025700, PMID 24071851, PMID 24508103, PMID 24582505, PMID 24862830, PMID 25037139, PMID 25109877, PMID 25265494, PMID 25326492, PMID 25399551, PMID 25884515, PMID 25980594, PMID 26287849, PMID 26342236, PMID 26352686, PMID 26433819, PMID 26460303, PMID 26873727, PMID 27460442, PMID 27480103, PMID 27532019, PMID 27729313, PMID 27853199, PMID 27864013, PMID 28444112, PMID 28646893, PMID 28915798, PMID 28961848, PMID 28976556, PMID 29320312, PMID 29350463, PMID 29477665, PMID 29552321, PMID 29573941
2014 (3), 2017 (3), 2018 (2), 2023 (2), P30CA016672 (2), U10CA180886 (2), 2009 (1), 2015 (1), 2016 (1), P30CA006516 (1), P30CA033572 (1), R01CA187238 (1), U01CA062490 (1), U10CA180821 (1), U10CA180888 (1)